40. Padcev

Seattle Genetics
(Seattle Genetics)

Active ingredient: enfortumab vedotin
Disease: metastatic bladder cancer
Peak sales estimate: >$5 billion
Approved: Dec. 18, 2019
Companies: Seattle Genetics and Astellas

The scoop: Seattle Genetics and Astellas scored their approval for Padcev nearly three months early, but that quick OK didn’t surprise analysts, who pointed to high unmet need in metastatic bladder cancer, a breakthrough designation and what SVB Leerink’s Andrew Berens, M.D., called “robust” data presented at this year’s ASCO meeting. There, the drug—which targets nectin-4, a protein on the surface of cells that’s highly expressed in bladder cancer—showed it could shrink tumors in 44% of patients in a single-arm phase 2 study and eliminate them in 12%. The companies got right to work on promotion with their team of just over 100 sales reps, but they’re not stopping there: They’re looking to move Padcev into earlier lines of treatment in tandem with Merck PD-1 superstar Keytruda. — Carly Helfand

 

40. Padcev

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.